Pharvaris

$19.65 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Pharvaris

Pharvaris B.V. operates as a clinical-stage company. The Company focuses on the discovery and development of novel oral B2-receptor antagonists for the treatment of patients. Pharvaris serves customers in the Netherlands and Switzerland.

Stock Analysis

last close $17.98
1-mo return 19.8%
3-mo return 13.6%
avg daily vol. 5.89T
52-week high 42.86
52-week low 13.14
market cap. $596M
forward pe -
annual div. -
roe -33.1%
ltg forecast 20.2%
dividend yield -
annual rev. $--
inst own. 80.4%
baraka

Subscribe now for daily local and international financial news

Subscribe